Myriad Genetics (MYGN)
Offers hereditary cancer, tumor profiling, prenatal, and GeneSight pharmacogenomic tests.
$4.17
vs last close+0.14 (+3.61%)
Something off on this page? Send us feedback.
Next report
Nov 2, 26
in 40 days
EPS estimate
−$0.16
Revenue estimate
$191.4M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Jul '26Nov '26
Reported$0.03−$0.03$0.05−$0.13$0.04−$0.09−$0.25Pending
Estimate$0.03−$0.05−$0.01−$0.01−$0.02−$0.06−$0.06−$0.16
Surprise0.0%+40.0%+600.0%−1,200.0%+300.0%−50.0%−331.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Jul '26Nov '26
Reported$210.6M$195.9M$213.1M$205.7M$209.8M$200.4M$190.7MPending
Estimate$210.3M$211.7M$205.2M$207.0M$207.4M$202.4M$206.0M$191.4M
Surprise+0.1%−7.5%+3.8%−0.6%+1.1%−1.0%−7.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.12 | — | — |
| Sep 2028 | −$0.12 | — | — |
| Jun 2028 | −$0.13 | — | — |
| Mar 2028 | −$0.14 | — | — |
| Dec 2027 | −$0.12 | — | — |
| Sep 2027 | −$0.13 | — | — |
| Jun 2027 | −$0.15 | — | — |
| Mar 2027 | −$0.15 | — | — |
| Dec 2026 | −$0.19 | — | — |
| Nov 2026 | −$0.16 | — | — |
| Jul 2026 | −$0.06 | −$0.25 | −331.9% |
| May 2026 | −$0.06 | −$0.09 | −50.0% |
| Feb 2026 | −$0.02 | $0.04 | +300.0% |
| Nov 2025 | −$0.01 | −$0.13 | −1,200.0% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.12 | — | — | $213.0M | — | — | — |
| Sep 2028 | −$0.12 | — | — | $207.4M | — | — | — |
| Jun 2028 | −$0.13 | — | — | $206.2M | — | — | — |
| Mar 2028 | −$0.14 | — | — | $203.8M | — | — | — |
| Dec 2027 | −$0.12 | — | — | $210.1M | — | — | — |
| Sep 2027 | −$0.13 | — | — | $205.6M | — | — | — |
| Jun 2027 | −$0.15 | — | — | $203.3M | — | — | — |
| Mar 2027 | −$0.15 | — | — | $203.9M | — | — | — |
| Dec 2026 | −$0.19 | — | — | $195.8M | — | — | — |
| Nov 2, 2026 | −$0.16 | — | — | $191.4M | — | — | — |
| Jul 30, 2026 | −$0.06 | −$0.25 | −331.9% | $206.0M | $190.7M | −7.4% | −46.7% |
| May 5, 2026 | −$0.06 | −$0.09 | −50.0% | $202.4M | $200.4M | −1.0% | −18.3% |
| Feb 23, 2026 | −$0.02 | $0.04 | +300.0% | $207.4M | $209.8M | +1.1% | +1.1% |
| Nov 3, 2025 | −$0.01 | −$0.13 | −1,200.0% | $207.0M | $205.7M | −0.6% | −21.0% |
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 24, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 7, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 3, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 3, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 13, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 6, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 13, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 5, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 21, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 6, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 2, 2017 | |||||||
| Feb 7, 2017 | |||||||
| Nov 1, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 3, 2016 | |||||||
| Feb 2, 2016 | |||||||
| Nov 3, 2015 | |||||||
| Aug 11, 2015 |